Dew, I would tend to agree about Cortex - it may just drift lower/sideways until we get to the FDA decision period this Fall. One of the big negatives from the poor DARPA results is that without the expected pop in the stock price, there can't be much additional warrant excercising, and Cortex will really need those added funds (projected cash level for year end '06 is only around $10 mil). So not only does Cortex desperately need to get the clinical hold lifted, they need it lifted on the first try (late September/early October) to avoid having to do another unfavorable PIPE in late'06/early'07.
I was also curious if you see the Zocor phenomenon (off-patent branded drugs being priced at/below the price of generics) becoming a future trend? If so, that could really put the generic companies at a disadvantage relative to where they were previously.
